(A–C) Cell lineages, Lin− cells, MPPs and HSCs
in the BM of control and ABX-treated mice at day 24 after sublethal TBI (n =
4–5). See also Figure S2G.
(D–E) BMT and HSCT analyses of control and ABX-treated mice under
steady state or at day 24 after sublethal TBI (n = 4–9).
(F) HSCs in the blood and BM of control and ABX-treated mice following
G-CSF treatment (n = 6–8).
(G–I) LSK cells and HSCs in the BM of control and ABX-treated
mice following E. coli infection or LPS challenge (n =
3–4). See also Figure S2H–I.
* p < 0.05, ** p < 0.01, *** p < 0.001. Error bars,
mean ± SEM.
See also Figure
S3 for niche, HSC localization, and cytokine availability
analyses.